Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8299 USD | -0.71% |
|
+7.31% | -74.23% |
Jul. 09 | Immunic Names President/COO, Chief Development Officer | MT |
Jul. 09 | Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-74.23% | 59.3M | |
+19.44% | 124B | |
+20.01% | 114B | |
+21.11% | 25.83B | |
-23.72% | 19.42B | |
-18.17% | 16.2B | |
-19.87% | 15.31B | |
+55.81% | 14.32B | |
+8.76% | 14.31B | |
-48.79% | 14.19B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating